Exhibit 10.329

|CONFIDENTIAL |  | REDACTED VERSION
|------------ |  | ----------------

[***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.

FUTURE BLOOD SCREENING ASSAY        ULTRIO ADDENDUM        AMENDING        AGREEMENT ENTERED INTO AS OF JUNE 11, 1998        BY AND BETWEEN        GEN-PROBE INCORPORATED, A
DELAWARE CORPORATION        AND        CHIRON CORPORATION

---



|1. |  | Definitions                                           |  | 2                                                                    
|-- |  | ----------------------------------------------------- |  | ---------------------------------------------------------------------
|   |  | 1.1                                                   |  | Agreement                                                            
|   |  | 1.2                                                   |  | Binder                                                               
|   |  | 1.3                                                   |  | Budget                                                               
|   |  | 1.4                                                   |  | Completion Date                                                      
|   |  | 1.5                                                   |  | FTE Labor Rate                                                       
|   |  | 1.6                                                   |  | Interim Events                                                       
|   |  | 1.7                                                   |  | Material Modification                                                
|   |  | 1.8                                                   |  | NIH Monies                                                           
|   |  | 1.9                                                   |  | Non-material Modification                                            
|   |  | 1.10                                                  |  | Product Requirements Document                                        
|   |  | 1.11                                                  |  | Project Management                                                   
|   |  | 1.12                                                  |  | Resource Plan                                                        
|   |  | 1.13                                                  |  | Software Requirements Specifications                                 
|   |  | 1.14                                                  |  | Technical Plan                                                       
|   |  | 1.15                                                  |  | Timeline                                                             
|   |  | 1.16                                                  |  | Ultrio Assay Product                                                 
|   |  | 1.17                                                  |  | Ultrio Development Costs                                             
|   |  | 1.18                                                  |  | Ultrio Development Program                                           
|2. |  | Ultrio Development Program                            |  | 3                                                                    
|   |  | 2.1                                                   |  | Objective                                                            
|   |  | 2.2                                                   |  | General Conduct of Development                                       
|   |  | 2.3                                                   |  | No Guarantee                                                         
|   |  | 2.4                                                   |  | Project Management                                                   
|   |  |                                                       |  | 2.4.1    Principles of Project Management                            
|   |  |                                                       |  | 2.4.2    Project Manager                                             
|   |  |                                                       |  | 2.4.3    Project Manager's Responsibilities                          
|   |  |                                                       |  | 2.4.4    Project Leaders                                             
|   |  |                                                       |  | 2.4.5    Reports                                                     
|   |  |                                                       |  | 2.4.6    Meetings of the Supervisory Board                           
|   |  | 2.5                                                   |  | Development Responsibilities                                         
|   |  |                                                       |  | 2.5.1    Principal Responsibility; General Statement                 
|   |  |                                                       |  | 2.5.2    Shared Responsibility                                       
|   |  |                                                       |  | 2.5.3    Principal and Shared Responsibility; Specific Allocation    
|   |  |                                                       |  | 2.5.4    Regulatory/Licensure                                        
|   |  |                                                       |  | 2.5.5    Project Leader Disagreements                                
|3. |  | Modifications                                         |  | 8                                                                    
|   |  | 3.1                                                   |  | Ultrio Development Program Definition                                
|   |  | 3.2                                                   |  | Modifications                                                        
|   |  |                                                       |  | 3.2.1    Request for Modifications                                   
|   |  |                                                       |  | 3.2.2    Non-Material Modifications                                  
|   |  | 3.3                                                   |  | Material Modifications                                               
|   |  |                                                       |  | 3.3.1    Request for Material Modifications                          
|   |  |                                                       |  | 3.3.2    Initial Analysis of Impact of Proposed Material Modification
|   |  |                                                       |  | 3.3.3    Preparation of Modified Ultrio Development Program          
|   |  |                                                       |  | 3.3.4    Acceptance of Modified Ultrio Development Program           
|   |  |                                                       |  | 3.3.5    Effective Date of Modified Ultrio Development Program       
|   |  | 3.4                                                   |  | Notice of Significant Changes                                        
|4. |  | Changes to Ultrio Assay Product after Completion Date |  | 10                                                                   
|   |  | 4.1                                                   |  | Process                                                              
|   |  | 4.2                                                   |  | Additional Work under Addendum                                       
|   |  |                                                       |  |                                                                      

i

---

|5.  |  | Ultrio Development Costs                   |  | 11                                                                                      
|--- |  | ------------------------------------------ |  | ----------------------------------------------------------------------------------------
|    |  | 5.1                                        |  | [***] Ultrio Development Costs and [***]                                                
|    |  | 5.2                                        |  | Definition and Calculation of Ultrio Development Costs; [***]                           
|    |  |                                            |  | 5.2.1    Ultrio Development Costs; FTE Labor Rate                                       
|    |  |                                            |  | 5.2.2    Comparison with Resource Plan                                                  
|    |  |                                            |  | 5.2.3    Methodology                                                                    
|    |  | 5.3                                        |  | Payment of Ultrio Development Costs                                                     
|    |  |                                            |  | 5.3.1    Accrued Ultrio Development Costs                                               
|    |  |                                            |  | 5.3.2    [***] Budgeted Payments                                                        
|    |  |                                            |  | 5.3.3    [***] True-Up Payments                                                         
|    |  |                                            |  | 5.3.4    Invoices                                                                       
|    |  | 5.4                                        |  | Dispute                                                                                 
|    |  | 5.5                                        |  | Right to Audit and Verify                                                               
|6.  |  | Manufacturing and Commercialization        |  | 14                                                                                      
|    |  | 6.1                                        |  | Definitions Relevant to Manufacturing and Commercialization Obligation                  
|    |  |                                            |  | 6.1.1    Applicable Purchase Price                                                      
|    |  |                                            |  | 6.1.2    Transfer Price                                                                 
|    |  |                                            |  | 6.1.3    Manufacturing Cost                                                             
|    |  |                                            |  | 6.1.4    Rare Reagents                                                                  
|    |  | 6.2                                        |  | Right to Audit and Verify                                                               
|    |  | 6.3                                        |  | Non-Commercial Products                                                                 
|    |  | 6.4                                        |  | Commercialization Budget                                                                
|7.  |  | License Grants                             |  | 16                                                                                      
|8.  |  | Addendum Effective Date; Term; Termination |  | 16                                                                                      
|    |  | 8.1                                        |  | Term of Ultrio Addendum                                                                 
|    |  | 8.2                                        |  | Termination for Breach                                                                  
|    |  |                                            |  | 8.2.1    Default                                                                        
|    |  |                                            |  | 8.2.2    Right to Cure Event of Default                                                 
|    |  |                                            |  | 8.2.3    Effect of Termination for Breach                                               
|    |  | 8.3                                        |  | Termination by Both Parties                                                             
|    |  |                                            |  | 8.3.1    Vote to Terminate                                                              
|    |  |                                            |  | 8.3.2    Effect of Notice Period on Termination by Both Parties                         
|    |  |                                            |  | 8.3.3    Effect of Termination by Both Parties                                          
|    |  | 8.4                                        |  | Termination by Either Party; Unilateral Withdrawal from Ultrio Development Program      
|    |  | 8.5                                        |  | Continuance of Ultrio Development Program following Unilateral Withdrawal or Termination
|    |  |                                            |  | 8.5.1    Election                                                                       
|    |  |                                            |  | 8.5.2    Funding and Conduct of Development                                             
|    |  |                                            |  | 8.5.3    Reimbursement of Development Costs                                             
|    |  |                                            |  | 8.5.4    Control of the Program upon Unilateral Funding                                 
|    |  |                                            |  | 8.5.5    Rights under Agreement                                                         
|9.  |  | Escalation                                 |  | 20                                                                                      
|    |  | 9.1                                        |  | Escalation Process                                                                      
|    |  | 9.2                                        |  | Remedies in Event of Default                                                            
|    |  | 9.3                                        |  | Survival                                                                                
|10. |  | No Other Amendment                         |  | 20                                                                                      
|11. |  | Counterparts                               |  | 20                                                                                      

ii

---

Future Blood Screening Assay

ULTRIO ADDENDUM

This Future Blood Screening AssayUltrio Addendum (the "Ultrio Addendum") is entered into, effective as of January 1, 2001 (the "Addendum
Effective Date") pursuant to and amending that certain Agreement entered into as of June 11, 1998 (the "Agreement") by and between Gen-Probe Incorporated, a Delaware corporation
("Gen-Probe") with a principal place of business at 10210 Genetic Center Drive, San Diego CA 92121, and Chiron Corporation, a Delaware corporation ("Chiron;" collectively with
Gen-Probe, the "parties") with a place of business at 4560 Horton Street, Emeryville, CA 94608.

Recitals

A.    The
parties entered into the Agreement as of June 11, 1998. The Agreement was amended by the following: (i) June 11, 1998 Supplemental letter
agreement, (ii) June 26, 1998 Addendum to Collaboration Agreement, (iii) June 30, 1998 Supplemental letter agreement, (iv) June 30, 1998 Consent, (v) 
December 7, 1999 Amendment to Collaboration Agreement, (vi) February 1, 2000 Amendment No. 2 to Collaboration Agreement, (vii) June 7, 2001 Supplemental
agreement no. 1 (Customer training and Support), (vii) October 30, 2001 Confidentiality and Joint Interest Agreement, and (ix) April 1, 2002 Amendment No. 3
(warehousing and shipping). In addition, the parties entered into certain settlements, described in Recital E below.

B.    In
the Agreement, the parties agreed to discuss, during the term thereof, the selection and establishment of one or more Development Programs for one or more Future Blood
Screening Assays to be conducted by the Blood Screening Instruments.

C.    The
parties have discussed the proposed development of a triplex TMA assay for the detection of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and/or
hepatitis B virus (HBV), on a semi-automated instrument system, which assay would fall within the definition of a "Future Blood Screening Assay" set forth in Section 1.30 of the
Agreement (the "Ultrio Assay").

D.    Gen-Probe
applied for and received a contract with the National Institutes of Health, Contract N01-HB-07148, effective
January 1, 2000, for which Chiron submitted a supporting letter, which contract as amended provides for, among other things, the partial funding of costs associated with the development of the
Ultrio Assay.

E.    The
parties submitted a number of disputes under the Agreement to arbitration pursuant to Section 13 of the Agreement, and in resolution of those disputes,
executed a Definitive Written Settlement Agreement, dated December 5, 2001, and a Short Form Agreement, dated November 16, 2001. These settlement agreements addressed certain aspects of
the development of the Ultrio Assay, the funding of such development, and eventual sale of any developed Ultrio Assay. All provisions of these settlement agreements which address the subject matter
addressed in this Addendum are expressly superceded by this Ultrio Addendum, except as expressly described herein.

F.     By
this Ultrio Addendum, the parties desire to include the Ultrio Assay to be conducted by one or more of the Blood Screening Instruments within the scope of the
provisions of the Agreement, as clarified and amended by the terms and conditions more particularly described in this Ultrio Addendum.

---

Agreement

NOW, THEREFORE, for and in consideration of the mutual covenants and agreements set forth in this Ultrio Addendum, the parties agree as follows:

1.Definitions.All capitalized terms used but not defined in this Ultrio Addendum shall have the meanings set
forth in the Agreement.



2

---



2.Ultrio Development Program.



3

---



4

---



5

---



6

---



Function

Principal Responsibility

Shared Responsibility[***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]



[***][***]



[***][***]

[***][***]



[***][***]

[***][***]



[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]



[***]


---



7

---







3.Modifications.



8

---



9

---



4.Changes to Ultrio Assay Product after Completion Date.



10

---



5.Ultrio Development Costs.



11

---



12

---



13

---



6.Manufacturing and Commercialization.



14

---





15

---



7.License Grants.

The
grant of licenses for the purpose of conducting the Ultrio Development Program shall be governed by Sections 3.2.6 and Section 9 of the Agreement. Chiron agrees that
Gen-Probe shall be [***].

8.Addendum Effective Date; Term; Termination.



16

---



17

---



18

---



19

---



9.Escalation.



10.No Other Amendment.Except as expressly set forth in this Ultrio Addendum, all other terms and conditions of
the Agreement, the parties' Definitive Written Settlement Agreement, dated December 5, 2001, and the Short Form Agreement, dated November 16, 2001, are hereby ratified and shall continue
in full force and effect. In the event of a conflict between the terms of this Ultrio Addendum and the Agreement, the terms of this Ultrio Addendum shall control. The provisions of this Ultrio
Addendum are intended to, and hereby, supercede any provisions in the Definitive Written Settlement Agreement entered into by and between the parties, dated December 5, 2001, and the Short Form
Agreement entered into by and between the parties, dated November 16, 2001, on the same subject matter.

11.Counterparts.This Ultrio Addendum may be executed in counterparts, each of such shall be deemed an
original, and all of which together shall constitute one and same instrument.

IN
WITNESS WHEREOF, the parties have caused this Ultrio Addendum to be executed and the persons signing below warrant that they are duly authorized to sign for and on behalf of the
respective parties.

|GEN-PROBE INCORPORATED,
a Delaware corporation |  | CHIRON CORPORATION,
a Delaware corporation
|---------------------------------------------- |  | ------------------------------------------
|By:                                            |  | /s/HANK NORDHOFF                          
|Its:                                           |  | CEO                                       
|Date:                                          |  | 3-24-03                                   

20

---

Schedule 1.16.

Description of Ultrio Assay Product

The Ultrio triplex assay is an in -vitro nucleic acid amplification test for the qualitative detection of human immunodeficiency virus Type 1 (HIV-1)
RNA, hepatitis B virus (HBV) DNA, and/or hepatitis C virus(HCV) RNA in human plasma for use in the Blood Screening Field. The Ultrio triplex assay will not discriminate between HIV-1, HBV
and HCV infection. The Ultrio assay is to be developed to run initially on the Procleix semi-automated instrument (eSAS).

HIV-1,
HBV and HCV discriminatory Probe reagents are in -vitro nucleic acid amplification tests for the qualitative detection of the specified virus and are provided with the
Ultrio triplex assay as part of the Ultrio Assay Product for use in discriminating between HIV-1, HBV and HCV in plasma following a positive result from the Ultrio triplex assay.

For
purposes of the foregoing Addendum, all of the Ultrio triplex assay and the associated discriminatory probe reagents are included within the definition of the "Ultrio Assay Product."

---

Schedule 5

Ultrio Development Costs

1.     Reimbursable
FTE Rate. Budget rates for future years will be based on [***] per FTE per calendar year until finalized each year per
section 5.2.1. Future calendar year FTE billing rates will be agreed to based on future annual budgets. In the absence of agreement, the FTE billing rate will be the then current billing rate
subject to true-up once new rates have been agreed.

2.     Ultrio
Development Costs included within FTE Labor Rate. Ultrio Development Costs included within FTE Labor Rate consist of all attributable costs associated with the
development of the Ultrio Assay Product and modifications to associated instrument system platforms (but excluding Tigris instruments) that may be required for such Ultrio Assay Product (calculated in
accordance with United States generally accepted accounting principles, or as otherwise mutually agreed in writing between the parties) incurred prior to the Completion Date and includes pilot
development; validation studies necessary for product and process licensure; clinical studies; licensing activities; and the manufacture and ultimate disposition of conformance lots of material,
calculated as follows:



---



3.     Ultrio
Development Costs not included within FTE Labor Rate.



---



Schedule 5.2.3

Ultrio Development Costs Calculation Methodology

[***]

---

Schedule 5.3.1

Accrued Ultrio Development Costs

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***][***]

[***][***]

[***][***]

[***][***]

[***][***]


---

Schedule 5.3.2

[***] Budgeted Payments

The party with the negative delta shall submit to the other party, on or before the end of the [***] during the term of the Ultrio
Development Program, an invoice setting forth the amount of the delta. In addition, any party owed by other an excess adjustment shall submit to the other party, on or before the end of the
[***] during the term of the Ultrio Development Program, an invoice setting forth the amount of the excess adjustment, providing reasonable detail for any Ultrio Development
Costs not previously invoiced and requesting payment of [***] of the total amount. Ultrio Development Costs by the invoicing party incurred to date and not yet reimbursed as
provided herein, providing reasonable detail for any Ultrio Development Costs not previously invoiced and requesting payment of [***] of the total amount. Each party shall pay
on or before the date specified therefore on the Technical Plan an amount equal to the lesser of (i) the Ultrio Development Costs reflected on the invoice submitted to such party on account of
such payment (together with amounts reflected on earlier invoices not previously reimbursed) or (ii) the amount of the payment described on the attached Technical Plan. To the extent that a
reimbursement payment is inadequate to cover the total Ultrio Development Costs incurred to date by a party, then each party shall carry over the balance to the next subsequent payment(s) until
finally reimbursed in full.

By
way of example, and using hypothetical dollars for actual expenditures, the calculation would operate as follows:

[***]

[***]

[***]

[***][***]

[***]



[***][***]

[***]

[***]

[***]


---

Schedule 5.3.3

[***] True-Up Payments
(sample methodology)

By way of example, and using hypothetical dollars for actual expenditures, the calculation would operate as follows: (true-up payment due to Chiron in
this case):

[***]

[***]

[***]

[***]

[***]

[***]

[***][***]

[***]



[***]

[***]

[***]

[***][***]

[***]

[***]

[***]

[***]



[***]


---

QuickLinks